NO20044672L - Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner - Google Patents

Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner

Info

Publication number
NO20044672L
NO20044672L NO20044672A NO20044672A NO20044672L NO 20044672 L NO20044672 L NO 20044672L NO 20044672 A NO20044672 A NO 20044672A NO 20044672 A NO20044672 A NO 20044672A NO 20044672 L NO20044672 L NO 20044672L
Authority
NO
Norway
Prior art keywords
parenteral
intravenous
diabetic foot
oxazolidinones
treatment
Prior art date
Application number
NO20044672A
Other languages
English (en)
Inventor
Carl Norden
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20044672L publication Critical patent/NO20044672L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Fremgangsmåte for behandling av en diabetisk fotinfeksjon i et pattedyr som inkluderer oral, parenteral eller intravenøs administrering av et farmasøytisk preparat inneholdende en oralt, parenteralt eller intravenøst effektiv mengde av et oksazolidinon.
NO20044672A 2002-03-29 2004-10-28 Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner NO20044672L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36910402P 2002-03-29 2002-03-29
PCT/US2003/008882 WO2003084534A1 (en) 2002-03-29 2003-03-21 Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections

Publications (1)

Publication Number Publication Date
NO20044672L true NO20044672L (no) 2004-12-23

Family

ID=28791924

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044672A NO20044672L (no) 2002-03-29 2004-10-28 Parenteral, intravenos og oral administrering av oksazolidinoner for behandling av diabetiske fotinfeksjoner

Country Status (16)

Country Link
US (1) US20030216330A1 (no)
EP (1) EP1490059A1 (no)
JP (1) JP2005527575A (no)
KR (1) KR20040095328A (no)
CN (1) CN1642543A (no)
AU (1) AU2003223334A1 (no)
BR (1) BR0308806A (no)
CA (1) CA2476545A1 (no)
IL (1) IL164195A0 (no)
MX (1) MXPA04009356A (no)
NO (1) NO20044672L (no)
NZ (1) NZ535648A (no)
PL (1) PL372661A1 (no)
RU (1) RU2354372C2 (no)
WO (1) WO2003084534A1 (no)
ZA (1) ZA200407734B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200404069A (en) * 2002-06-28 2004-03-16 Upjohn Co Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent
JP4579502B2 (ja) * 2003-05-02 2010-11-10 キヤノン株式会社 構造体及びその製造方法、該構造体を含むトナー並びにそれを用いた画像形成方法及び装置
AU2004267007C1 (en) 2003-06-03 2010-04-29 Melinta Subsidiary Corp. Biaryl heterocyclic compounds and methods of making and using the same
US8324398B2 (en) 2003-06-03 2012-12-04 Rib-X Pharmaceuticals, Inc. Process for the synthesis of biaryl oxazolidinones
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
WO2006008640A1 (en) * 2004-07-15 2006-01-26 Pharmacia & Upjohn Company Llc Non-aqueous suspension containing a drug having an unpleasant taste
TW200612923A (en) * 2004-07-29 2006-05-01 Ferrer Int Oxazolidinone compounds and compositions and methods related thereto
US8399660B2 (en) 2005-06-08 2013-03-19 Rib-X Pharmaceuticals, Inc. Process for the synthesis of triazoles
EP1745784A1 (en) * 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
EP1899331B1 (en) 2005-06-29 2009-11-25 Pharmacia & Upjohn Company LLC Homomorpholine oxazolidinones as antibacterial agents
US9427468B2 (en) * 2007-08-22 2016-08-30 Trustees Of Dartmouth College Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus
UY32493A (es) * 2009-03-16 2010-10-29 Astrazeneca Ab " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones"
WO2012082992A1 (en) * 2010-12-15 2012-06-21 Biovista, Inc. Compositions and methods for cancer treatment

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4705799A (en) * 1983-06-07 1987-11-10 E. I. Du Pont De Nemours And Company Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5043443A (en) * 1988-07-29 1991-08-27 Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5182403A (en) * 1988-09-15 1993-01-26 The Upjohn Company Substituted 3(5'indazolyl) oxazolidin-2-ones
US5225565A (en) * 1988-09-15 1993-07-06 The Upjohn Company Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
AU667198B2 (en) * 1991-11-01 1996-03-14 Pharmacia & Upjohn Company Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
JP3558088B2 (ja) * 1992-12-08 2004-08-25 ファルマシア・アンド・アップジョン・カンパニー トロポン−置換のフェニルオキサゾリジノン抗菌剤
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
JP3698724B2 (ja) * 1993-11-22 2005-09-21 ファルマシア・アンド・アップジョン・カンパニー 置換−ヒドロキシアセチルピペラジンフェニルオキサゾリジノンのエステル
DE4425609A1 (de) * 1994-07-20 1996-01-25 Bayer Ag Benzofuranyl- und Benzothienyloxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE19514313A1 (de) * 1994-08-03 1996-02-08 Bayer Ag Benzoxazolyl- und Benzothiazolyloxazolidinone
BR9509673A (pt) * 1994-11-15 1997-09-30 Upjohn Co Compostos e uso dos mesmos
HRP960159A2 (en) * 1995-04-21 1997-08-31 Bayer Ag Benzocyclopentane oxazolidinones containing heteroatoms
CA2228647A1 (en) * 1995-09-01 1997-03-13 Pharmacia & Upjohn Company Phenyloxazolidinones having a c-c bond to 4-8 membered heterocyclic rings
DE19601264A1 (de) * 1996-01-16 1997-07-17 Bayer Ag Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone
DE19604223A1 (de) * 1996-02-06 1997-08-07 Bayer Ag Neue substituierte Oxazolidinone
WO1999037630A1 (en) * 1998-01-23 1999-07-29 Versicor, Inc. Oxazolidinone combinatorial libraries, compositions and methods of preparation
MY122454A (en) * 1998-06-05 2006-04-29 Upjohn Co Use of oxazolidinones for the preparation of a medicament for transdermal delivery
JP2004501965A (ja) * 2000-06-30 2004-01-22 ファルマシア・アンド・アップジョン・カンパニー 細菌感染を治療するための組成物および方法

Also Published As

Publication number Publication date
PL372661A1 (en) 2005-07-25
CA2476545A1 (en) 2003-10-16
CN1642543A (zh) 2005-07-20
BR0308806A (pt) 2005-01-04
IL164195A0 (en) 2005-12-18
ZA200407734B (en) 2005-06-24
JP2005527575A (ja) 2005-09-15
EP1490059A1 (en) 2004-12-29
KR20040095328A (ko) 2004-11-12
MXPA04009356A (es) 2005-01-25
NZ535648A (en) 2007-05-31
RU2004131830A (ru) 2005-04-10
AU2003223334A1 (en) 2003-10-20
WO2003084534A1 (en) 2003-10-16
RU2354372C2 (ru) 2009-05-10
US20030216330A1 (en) 2003-11-20

Similar Documents

Publication Publication Date Title
CY1125077T1 (el) Αγωγη της ανεπαρκειας και ελλειψης βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3
CO5700796A2 (es) Composiciones que contienen piperacilina y tazobactam utiles para inyecciones
AR047779A1 (es) Composiciones y metodos para tratar diabetes
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
NO20034549L (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO20075042L (no) Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer
BRPI0408784A (pt) método para usar um composto
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
BR0307066A (pt) Dispositivo médico resistente a infecção
BRPI0409523A (pt) método para o tratamento da dor neuropática, método de identificação de um composto e composição farmacêutica
DE602004021644D1 (de) Gyraseinhibitoren und deren verwendungen
NO20083036L (no) Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
CY1106771T1 (el) Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
BR0308806A (pt) Uso de oxazolidinonas para tratar infecções do tipo pé diabético
ATE357928T1 (de) Pharmazeutische zusammensetzung für thrombinpeptidderivaten
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
BR0110382A (pt) Utilização de composições antibióticas azalida para o tratamento ou prevenção de uma infecção causada por bactérias ou protozoários em mamìferos
CL2024003328A1 (es) Métodos para el tratamiento de linfoma.
BRPI0517650A (pt) uso de ranolazina em combinação com pelo menos um agente de remodelamento para reversão de remodelamento ventricular esquerdo no tratamento de insuficiência cardìaca
BRPI0516583A (pt) composição farmacêutica e método de tratamento de uma infecção bacteriana
DK1096934T3 (da) Oxazolidinoner til behandling af öjeninfektioner
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
NO20070763L (no) Kombinasjonsterapi med radiomerket anti-CD20-antistoff i behandlingen av B-cellelymfom

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application